Key Nutrient:  N-Acetyl Cysteine

N-Acetyl Cysteine is a derivative of the amino acid L-cysteine, and is a crucial precursor in the formation of the antioxidant glutathione.  N-Acetyl Cysteine boosts glutathione levels.

Glutathione (GSH) is the predominant water-soluble antioxidant in cells.  Virtually all cells require glutathione for viability and function.  Glutathione scavenges destructive free radical, and neutralizes hydrogen peroxide.  Blood glutathione levels decline with age.

N-Acetyl Cysteine is in GO2 because it has been shown to have the following effects:

Scientifically demonstrated benefits of NAC:

NAC has shown efficacy as a complimentary therapy in the following:

References

  1. Akerlund B, Jarstrand C, Lindeke B, et al. Effect of N-acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Eur J Clin Pharmacol 1996;50:457-461.
  2. Arstall MA, Yang J, Stafford I, et al. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation 1995;92:2855-2862.
  3. Aruoma OI, Halliwell B, Hoey BM, and Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6: 593–597, 1989.
  4. Baier JE, Neumann HA, Moeller T, et al. Radiation protection through cytokine release by N-acetylcysteine. Strahlenther Onkol 1996;172:91-98.
  5. Bannai S and Tateishi N. Role of membrane transport in metabolism and function of glutathione in mammals. J Membr Biol 89: 1–8, 1986
  6. Banner W Jr, Koch M, Capin DM, et al. Experimental chelation therapy in chromium, lead, and boron intoxication with N-acetylcysteine and other compounds. Toxicol Appl Pharmacol 1986;83:142-147.
  7. Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997;156:1897-1901.
  8. Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 1986;31:217-222.
  9. Bracht A. N-acetylcysteine stimulates hepatic glycogen deposition in the rat. Res Commun Chem Pathol Pharmacol 83:87-92; 1994.
  10. Breithaupt TB, Vazquez A, Baez I, Eylar EH. The suppression of T cell function and NF(kappa)B expression by serine protease inhibitors is blocked by N-acetylcysteine. Cell Immunol 1996;173:124-130.
  11. Buchter A, Peter H, Bolt HM. N-Acetylcysteine as an antidote in accidental acrylonitrile poisoning. Int Arch Occup Environ Health 1984;53:311-319.
  12. Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989;36:127-131.
  13. Cazzulani P, Cassin M, and Ceserani R. Increased endurance to physical exercise in mice given oral reduced glutathione (GSH). Med Sci Res 19: 543–544, 1991.
  14. Ceconi C, Curello S, Cargnoni A, et al. The role of glutathione status in the protection against ischaemic and reperfusion damage: effects of N-acetyl cysteine. J Mol Cell Cardiol 1988;20:5-13.
  15. Chung FL, Kelloff G, Steele V, et al. Chemopreventive efficacy of arylalkyl isothiocyanates and N-acetylcysteine for lung tumorigenesis in Fischer rats. Cancer Res 1996;56:772-778.
  16. Corcoran GB, Wong BK. Role of glutathione in prevention of acetaminophen-induced hepatotoxicity by N-acetyl-L-cysteine in vivo: Studies with N-acetyl-D-cysteine in mice. J Pharm Exp Ther 1986;238:54-61.
  17. Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol 38: 205–227, 1997
  18. Cotgreave IA, Berggren M, Jones TW, et al. Gastrointestinal metabolism of N-acetylcysteine in the rat, including an assay for sulfite in biological systems. Biopharm Drug Dispos 1987;8:377-386.
  19. De Caro L, Ghizzi A, Costa R, et al. Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneim Forsch 1989;39:382-385.
  20. De Flora S, Bennicelli C, Camoirano A, et al. In vivo effects of N-acetylcysteine on glutathione metabolism and on the biotransformation of carcinogenic and/or mutagenic compounds. Carcinogenesis 1985;6:1735-1745.
  21. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997;10:1535-1541.
  22. De Flora S, Rossi GA, De Flora A. Metabolic, desmutagenic and anticarcinogenic effects of N-acetylcysteine. Respiration 1986;50:S43-S49.
  23. De Vries N, De Flora S. N-Acetyl-l-Cysteine. J Cell Biochem 1993;17F:S270-S277.
  24. Devlin J, Ellis AE, McPeake J, et al. N-acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfunction. Crit Care Med 1997;25:236-242.
  25. Diaz PT, Brownstein E, and Clanton TL. Effects of N-acetylcysteine on in vitro diaphragm function are temperature dependent. J Appl Physiol 77: 2434–2439, 1994
  26. Doroshow JH, Locker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest 1981;68:1053-1064.
  27. Droge W, Eck H-P, Mihm S. HIV-induced cysteine deficiency and T-cell dysfunction - a rationale for treatment with N-acetylcysteine. Immun Today 1992;13:211-214.
  28. Eklund A, Eriksson O, Hakansson L, et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J 1988;1:832-838.
  29. Gavish D, Breslow JL. Lipoprotein(a) reduction by N-acetylcysteine. Lancet 1991;337:203-204.
  30. Girardi G, Elias MM. Effectiveness of N-acetylcysteine in protecting against mercuric chloride-induced nephrotoxicity. Toxicology 1991;67:155-164.
  31. Gogu SR, Agrawal KC. The protective role of zinc and N-acetylcysteine in modulating zidovudine induced hematopoietic toxicity. Life Sci 1996;59:1323-1329.
  32. Gohil K, Viguie C, Stanley WC, Brooks GA, and Packer L. Blood glutathione oxidation during human exercise. J Appl Physiol 64: 115–119, 1988
  33. Henderson P, Hale TW, Shum S, Habersang RW. N-Acetylcysteine therapy of acute heavy metal poisoning in mice. Vet Hum Toxicol 1985;27:522-525.
  34. Herzenberg LA, De Rosa SC, Dubs JG, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA 1997;94:1967-1972.
  35. Hida W, Shindoh C, Satoh J, et al. N-acetylcysteine inhibits loss of diaphragm function in streptozotocin-treated rats. Am J Respir Crit Care Med 1996;153:1875-1879.
  36. Hoffer E, Baum Y, Tabak A, Taitelman U. N-acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. Toxicol Lett 1996;84:7-12.
  37. Horowitz JD, Henry CA, Syrjanen ML, et al. Nitroglycerine/N-acetylcysteine in the management of unstable angina pectoris. Eur Heart J 1988;9:95-100.
  38. Hultberg B, Andersson A, Isaksson A. The effects of homocysteine and copper ions on the concentration and redox status of thiols in cell line cultures. Clin Chim Acta 1997;262:39-51.
  39. Hurd RW, Wilder BJ, Helveston WR, Uthman BM. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology 1996;47:1264-1268.
  40. Issels RD, Nagele A, Eckert KG, Wilmanns W. Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine. Biochem Pharmacol 1988;37:881-888.
  41. Jackson IM, Barnes J, Cooksey P. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study. J Int Med Res 1984;12:198-206.
  42. Johnston SC, Pelletier LL Jr. Enhanced hepatotoxicity of acetaminophen in the alcoholic patient. Two case reports and a review of the literature. Medicine (Baltimore) 1997;76:185-191.
  43. Jones AL, Jarvie DR, Simpson D, et al. Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. Aliment Pharmacol Ther 1997;11:787-791.
  44. Kinscherf R; Fischbach T; Mihm S; et al. Effect of glutathione depletion and oral N-acetyl-cysteine treatment on CD4+ and CD8+ cells. FASEB J 8:448-451; 1994.
  45. Klein-Schwartz W, Oderda GM. Adsorption of oral antidotes for acetaminophen poisoning (methionine and N-acetylcysteine) by activated charcoal. Clin Toxicol 1981;18:283-290.
  46. Kleinveld HA, Demacker PNM, Stalenhoef APH. Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy subjects. Eur J Clin Pharmacol 1992;43:639-642.
  47. Kobrinsky NL, Hartfield D, Horner H, et al. Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue. Cancer Invest 1996;14:202-210.
  48. Kopke R, Bielefeld E, Liu J, et al. Prevention of impulse noise-induced hearing loss with antioxidants. Acta Otolaryngol 2005;125(3):235-43.
  49. Lands LC, Grey VL, and Smountas AA. Effect of supplementation with a cysteine donor on muscular performance. J Appl Physiol 87: 1381–1385, 1999
  50. Livardjani F, Lediga M, Koppa P, et al. Lung and blood superoxide dismutase activity in mercury vapor exposed rats: effect of N-acetylcysteine treatment. Toxicology 66:289-295; 1991.
  51. Liu AJ, Richardson MA. Effects of N-acetylcysteine on experimentally induced esophageal eye injury. Ann Otol Rhinol Laryngol 1985;94:477-482.
  52. Lorber A, Baumgartner WA, Bovt RA, et al. Clinical application for heavy metal-complexing potential of N-acetylcysteine. J Clin Pharmacol 1973;13:332-336.
  53. Martin DS, Willis SE, Cline DM. N-acetylcysteine in the treatment of human arsenic poisoning. J Am Board Fam Pract 1990;3:293-296.
  54. Medved I, Brown MJ, Bjorksten AR, Leppik JA, Sostaric S, and McKenna MJ. N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans. J Appl Physiol 94: 1572–1582, 2003.
  55. Medved I, Brown MJ, Bjorksten AR, and McKenna MJ. Effects of intravenous N-acetylcysteine infusion on time to fatigue and potassium regulation during prolonged cycling exercise. J Appl Physiol 96: 211–217, 2004Millar AB, Pavia D, Agnew JE, et al. Effect of oral N-acetylcysteine on mucus clearance. Br J Dis Chest 1985;79:262-266.
  56. Morris PE;Bernard GR. Significance of glutathione in lung disease and implications for therapy. Am J Med Sci 307:119-127;1994
  57. Nakata K, Kawase M, Ogino S, et al. Effects of age on levels of cysteine, glutathione and related enzyme activities in livers of mice and rats and an attempt to replenish hepatic glutathione level of mouse with cysteine derivatives. Mech Ageing Dev 1996;90:195-207.
  58. Novelli GP, Falsini S, and Bracciotti G. Exogenous glutathione increases endurance to muscle effort in mice. Pharmacol Res 23: 149–155, 1991
  59. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 1988;34:77-82.
  60. Omara FO, Blakley BR, Bernier J, Fournier M. Immunomodulatory and protective effects of N-acetylcysteine in mitogen-activated murine splenocytes in vitro. Toxicology 1997;116:219-226.
  61. Parr GD, Huitson A. Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis. Br J Dis Chest 1987;81:341-348.
  62. Pastor A, Collado PS, Almar M, Gonzalez-Gallego J. Antioxidant enzyme status in biliary obstructed rats: effects of N-acetylcysteine. J Hepatol 1997;27:363-370.
  63. Pela R, Calcagni AM, Subiaco S, et al. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration 1999;66(6):495-500.
  64. Pratt S, Ioannides C. Mechanism of the protective action of N-acetylcysteine and methionine against paracetamol toxicity in the hamster. Arch Toxicol 1985;57:173-177.
  65. Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled release tablets in patients with chronic bronchitis. Eur Respir J. 1988, 1, 351-355.
  66. Reid MB, Stokic DS, Koch SM, Khawli FA, and Leis AA. N-acetylcysteine inhibits muscle fatigue in humans. J Clin Invest 94: 2468–2474, 1994
  67. Roberts RL, Aroda VR, Ank BJ. N-acetylcysteine enhances antibody-dependent cellular cytotoxicity in neutrophils and mononuclear cells from healthy adults and human immunodeficiency virus-infected patients. J Infect Dis 1995;172:1492-1502.
  68. Rogers DF, Jeffery PK. Inhibition by oral N-acetylcysteine of cigarette smoke-induced "bronchitis" in the rat. Exp Lung Res 1986;10:267-283.
  69. Rogers DF, Godfrey RW, Majumdar S, Jeffery PK. Oral N-acetylcysteine speeds reversal of cigarette smoke-induced mucous cell hyperplasia in the rat. Exp Lung Res 1988;14:19-35.
  70. Sastre J, Asensi M, Gasco E, Pallardo FV, Ferrero JA, Furukawa T, and Vina J. Exhaustive physical exercise causes oxidation of glutathione status in blood: prevention by antioxidant administration. Am J Physiol Regul Integr Comp Physiol 263: R992–R995, 1992
  71. Sen CK, Atalay M, and Hanninen O. Exercise-induced oxidative stress: glutathione supplementation and deficiency. J Appl Physiol 77: 2177–2187, 1994
  72. Sen CK, Marin E, Kretzschmar M, and Hanninen O. Skeletal muscle and liver glutathione homeostasis in response to training, exercise, and immobilization. J Appl Physiol 73: 1265–1272, 1992.
  73. Sen CK and Packer L. Thiol homeostasis and supplements in physical exercise. Am J Clin Nutr 72: 653S–669S, 2000.
  74. Shindoh C, DiMarco A, Thomas A, Manubay P, and Supinski G. Effect of N-acetylcysteine on diaphragm fatigue. J Appl Physiol 68: 2107–2113, 1990
  75. Shum S, Skarbovig J, Habersang RW. Acute lethal arsenite poisoning in mice: effect of treatment with N-acetylcysteine, D-penicillamine and dimercaprol on survival time. Vet Hum Toxic 1981;23:39-42.
  76. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988;319:1557-1562.
  77. Sochman J, Vrbska J, Musilova B, Rocek M. Infarct size limitation: acute N-acetylcysteine defense (ISLAND trial): preliminary analysis and report after the first 30 patients. Clin Cardiol 1996;19:94-100.
  78. Spies C, Giese C, Meier-Hellmann A, et al. The effect of prophylactically administered N-acetylcysteine on clinical indicators for tissue oxygenation during hyperoxic ventilation in cardiac risk patients. Anaesthesist 1996;45:343-350.
  79. Supinski GS, Stofan D, Ciufo R, and DiMarco A. N-acetylcysteine administration and loaded breathing. J Appl Physiol 79: 340–347, 1995 Stavem K. Anaphylactic reaction to N-acetylcysteine after poisoning with paracetamol. Tidsskr Nor Laegeforen 1997;117:2038-2039. [Article in Norwegian]
  80. Svensson MB, Ekblom B, Cotgreave IA, Norman B, Sjoberg B, Ekblom O, Sjodin B, and Sjodin A. Adaptive stress response of glutathione and uric acid metabolism in man following controlled exercise and diet. Acta Physiol Scand 176: 43–56, 2002
  81. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
  82. Travaline JM, Sudarshan S, Roy BG, Cordova F, Leyenson V, and Criner GJ. Effect of N-acetylcysteine on human diaphragm strength and fatigability. Am J Respir Crit Care Med 156: 1567–1571, 1997.
  83. Ungheri D, Pisani C, Sanson G, et al. Protective effect of n-acetylcysteine in a model of influenza infection in mice. Int J Immunopathol Pharmacol 2000;13(3):123-128
  84. ecchiarelli A, Dottorini M, Pietrella D, et al. Macrophage activation by N-acetyl-cysteine in COPD patients. Chest 105:806-811; 1994.
  85. Wagner PD, Mathieu-Costello O, Bebout DE, et al. Protection against pulmonary O2 toxicity by N-acetylcysteine. Eur Respir J 1989;2:116-126.
  86. Walters MT, Rubin CE, Keightley SJ, Ward CD. A double-blind, cross-over, study of oral N-acetylcysteine in Sjogren's syndrome. Scand J Rheumatol Suppl 1986;61:253-258.
  87. Wang PH, Yang MJ, Lee WL, et al. Acetaminophen poisoning in late pregnancy. A case report. J Reprod Med 1997;42:367-371.
  88. Wegener T, Sandhagen B, Saldeen T. Effect of N-acetylcysteine on pulmonary damage due to microembolism in the rat. Eur J Respir Dis 1987;70:205-212.
  89. Wiklund O, Fager G, Andersson A, et al. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. Atherosclerosis 1996;119:99-106.
  90. Wu J, Levy M, Black PH. 2-Mercaptoethanol and n-acetylcysteine enhance T cell colony formation in AIDS and ARC. Clin Exp Immunol 1989;77:7-10.
  91. Yim CY, Hibbs JB Jr, McGregor JR, et al. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J Immunol 152:5796-5805; 1994.urolithiasis. Br J Urol 74:288-293; 1994.